Summary

The global Targeted Protein Degrader Technology market size was US$ 133 million in 2025 and is forecast to reach a readjusted size of US$ 422 million by 2032 with a CAGR of 18.3% during the forecast period 2026-2032.
Targeted protein degradation technology involves the design and development of small molecules or biologics that selectively bind to specific proteins within cells and mark them for degradation by the cell's natural protein degradation machinery, such as the ubiquitin-proteasome system or lysosomes. This approach enables the removal of disease-causing or undesirable proteins, including those considered "undruggable" by traditional small molecule inhibitors, by harnessing the body's own degradation pathways. Typically, targeted protein degraders consist of a ligand that binds to the target protein, a linker, and a component that recruits the cellular degradation machinery. This technology holds promise for the treatment of various diseases, including cancer and genetic disorders, by targeting proteins involved in disease pathways with high specificity and efficacy.
Targeted protein degradation (TPD) technology is experiencing rapid growth and increasing interest across the biopharmaceutical industry, driven by its ability to address previously "undruggable" targets and offer novel therapeutic strategies for cancer, neurodegenerative diseases, and autoimmune disorders. The market is characterized by a surge in strategic partnerships, licensing deals, and R&D investments from both established pharmaceutical companies and emerging biotech firms. Key technological platforms—such as PROTACs (proteolysis-targeting chimeras), molecular glues, and autophagy-based degraders—are progressing through clinical pipelines, with several candidates entering early-phase trials. As the field matures, advancements in degrader design, improved target specificity, and favorable regulatory developments are expected to accelerate adoption and expand therapeutic applications.
The global Targeted Protein Degrader Technology market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on revenue and forecasts across regions, by Type, and by Application for 2021-2032.
Market Segmentation
By Company:
Arvinas
C4 Therapeutics
Kymera Therapeutics
Nurix
Pfizer
Novartis
MSD
Foghorn Therapeutics
Dialectic Therapeutics
Accutar Biotech
Cullgen
Bristol-Myers Squibb
Monte Rosa Therapeutics
Proxygen
Dunad Therapeutics
Astellas
Origami Therapeutics
NEOsphere Biotechnologies
Ubiquigent
Kangpu Biopharmaceuticals
Ranok Therapeutics
BeiGene
Hinova Pharma
Haisco Pharmaceutical
CTTQ
Segment by Type
PROTAC
Molecular Glues
Other Ubiquitin-Proteasome System Technologies
Lysosomal System Technologies
Segment by Application
Prostate Cancer
Breast Cancer
Lymphoma
Others
By Region
Macro-Region
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Micro-Local Markets
North America
Europe
Asia-Pacific
Latin America
Middle East & Africa
(Additional regions can be customized based on client needs.)
Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term)
Chapter 2: Quantitative analysis of Targeted Protein Degrader Technology market size and growth potential at global, regional, and country levels
Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus)
Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets
Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities
Chapter 6: Regional revenue breakdown by company, type, application and customer
Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments
Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 9: Actionable conclusions and strategic recommendations.
Why This Report?
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Targeted Protein Degrader Technology value chain, addressing:
- Market entry risks/opportunities by region
- Product mix optimization based on local practices
- Competitor tactics in fragmented vs. consolidated markets

ページTOPに戻る

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Market by Type
1.2.1 Global Market Size and Growth by Type: 2021 vs 2025 vs 2032
1.2.2 PROTAC
1.2.3 Molecular Glues
1.2.4 Other Ubiquitin-Proteasome System Technologies
1.2.5 Lysosomal System Technologies
1.3 Market by Application
1.3.1 Global Market Share by Application: 2021 vs 2025 vs 2032
1.3.2 Prostate Cancer
1.3.3 Breast Cancer
1.3.4 Lymphoma
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered

2 Global Growth Trends
2.1 Global Targeted Protein Degrader Technology Market Perspective (2021-2032)
2.2 Global Market Size by Region: 2021 vs 2025 vs 2032
2.3 Global Targeted Protein Degrader Technology Market Share by Revenue, by Region (2021-2026)
2.4 Global Targeted Protein Degrader Technology Revenue Forecast by Region (2027-2032)
2.5 Major Regions and Emerging Markets Analysis
2.5.1 North America Targeted Protein Degrader Technology Market Size and Prospective (2021-2032)
2.5.2 Europe Targeted Protein Degrader Technology Market Size and Prospective (2021-2032)
2.5.3 Asia-Pacific Targeted Protein Degrader Technology Market Size and Prospective (2021-2032)
2.5.4 Latin America Targeted Protein Degrader Technology Market Size and Prospective (2021-2032)
2.5.5 Middle East & Africa Targeted Protein Degrader Technology Market Size and Prospective (2021-2032)

3 Breakdown Data by Type
3.1 Global Targeted Protein Degrader Technology Historical Market Size by Type (2021-2026)
3.2 Global Targeted Protein Degrader Technology Forecasted Market Size by Type (2027-2032)
3.3 Representative Players for Different Types of Targeted Protein Degrader Technology

4 Breakdown Data by Application
4.1 Global Targeted Protein Degrader Technology Historical Market Size by Application (2021-2026)
4.2 Global Targeted Protein Degrader Technology Forecasted Market Size by Application (2027-2032)
4.3 New Sources of Growth in Targeted Protein Degrader Technology Applications

5 Competitive Landscape by Players
5.1 Global Top Players by Revenue
5.1.1 Global Top Targeted Protein Degrader Technology Players by Revenue (2021-2026)
5.1.2 Global Targeted Protein Degrader Technology Market Share by Revenue, by Players (2021-2026)
5.2 Global Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
5.3 Players Covered: Ranking by Targeted Protein Degrader Technology Revenue
5.4 Global Targeted Protein Degrader Technology Market Concentration Analysis
5.4.1 Global Targeted Protein Degrader Technology Market Concentration Ratio (CR5 and HHI)
5.4.2 Global Top 10 and Top 5 Companies by Targeted Protein Degrader Technology Revenue in 2025
5.5 Global Key Players of Targeted Protein Degrader Technology Head Offices and Areas Served
5.6 Global Key Players of Targeted Protein Degrader Technology, Product and Application
5.7 Global Key Players of Targeted Protein Degrader Technology, Date of Entry into This Industry
5.8 Mergers & Acquisitions, Expansion Plans

6 Region Analysis
6.1 North America Market: Players, Segments, Downstream and Major Customers
6.1.1 North America Targeted Protein Degrader Technology Revenue by Company (2021-2026)
6.1.2 North America Market Size by Type
6.1.2.1 North America Targeted Protein Degrader Technology Market Size by Type (2021-2026)
6.1.2.2 North America Targeted Protein Degrader Technology Market Share by Type (2021-2026)
6.1.3 North America Market Size by Application
6.1.3.1 North America Targeted Protein Degrader Technology Market Size by Application (2021-2026)
6.1.3.2 North America Targeted Protein Degrader Technology Market Share by Application (2021-2026)
6.1.4 North America Targeted Protein Degrader Technology Major Customers
6.1.5 North America Market Trends and Opportunities
6.2 Europe Market: Players, Segments, Downstream and Major Customers
6.2.1 Europe Targeted Protein Degrader Technology Revenue by Company (2021-2026)
6.2.2 Europe Market Size by Type
6.2.2.1 Europe Targeted Protein Degrader Technology Market Size by Type (2021-2026)
6.2.2.2 Europe Targeted Protein Degrader Technology Market Share by Type (2021-2026)
6.2.3 Europe Market Size by Application
6.2.3.1 Europe Targeted Protein Degrader Technology Market Size by Application (2021-2026)
6.2.3.2 Europe Targeted Protein Degrader Technology Market Share by Application (2021-2026)
6.2.4 Europe Targeted Protein Degrader Technology Major Customers
6.2.5 Europe Market Trends and Opportunities
6.3 Asia-Pacific Market: Players, Segments, Downstream and Major Customers
6.3.1 Asia-Pacific Targeted Protein Degrader Technology Revenue by Company (2021-2026)
6.3.2 Asia-Pacific Market Size by Type
6.3.2.1 Asia-Pacific Targeted Protein Degrader Technology Market Size by Type (2021-2026)
6.3.2.2 Asia-Pacific Targeted Protein Degrader Technology Market Share by Type (2021-2026)
6.3.3 Asia-Pacific Market Size by Application
6.3.3.1 Asia-Pacific Targeted Protein Degrader Technology Market Size by Application (2021-2026)
6.3.3.2 Asia-Pacific Targeted Protein Degrader Technology Market Share by Application (2021-2026)
6.3.4 Asia-Pacific Targeted Protein Degrader Technology Major Customers
6.3.5 Asia-Pacific Market Trends and Opportunities
6.4 Latin America Market: Players, Segments, Downstream and Major Customers
6.4.1 Latin America Targeted Protein Degrader Technology Revenue by Company (2021-2026)
6.4.2 Latin America Market Size by Type
6.4.2.1 Latin America Targeted Protein Degrader Technology Market Size by Type (2021-2026)
6.4.2.2 Latin America Targeted Protein Degrader Technology Market Share by Type (2021-2026)
6.4.3 Latin America Market Size by Application
6.4.3.1 Latin America Targeted Protein Degrader Technology Market Size by Application (2021-2026)
6.4.3.2 Latin America Targeted Protein Degrader Technology Market Share by Application (2021-2026)
6.4.4 Latin America Targeted Protein Degrader Technology Major Customers
6.4.5 Latin America Market Trends and Opportunities
6.5 Middle East & Africa Market: Players, Segments, Downstream and Major Customers
6.5.1 Middle East & Africa Targeted Protein Degrader Technology Revenue by Company (2021-2026)
6.5.2 Middle East & Africa Market Size by Type
6.5.2.1 Middle East & Africa Targeted Protein Degrader Technology Market Size by Type (2021-2026)
6.5.2.2 Middle East & Africa Targeted Protein Degrader Technology Market Share by Type (2021-2026)
6.5.3 Middle East & Africa Market Size by Application
6.5.3.1 Middle East & Africa Targeted Protein Degrader Technology Market Size by Application (2021-2026)
6.5.3.2 Middle East & Africa Targeted Protein Degrader Technology Market Share by Application (2021-2026)
6.5.4 Middle East & Africa Targeted Protein Degrader Technology Major Customers
6.5.5 Middle East & Africa Market Trends and Opportunities

7 Key Player Profiles
7.1 Arvinas
7.1.1 Arvinas Company Details
7.1.2 Arvinas Business Overview
7.1.3 Arvinas Targeted Protein Degrader Technology Introduction
7.1.4 Arvinas Revenue in Targeted Protein Degrader Technology Business (2021-2026)
7.1.5 Arvinas Recent Development
7.2 C4 Therapeutics
7.2.1 C4 Therapeutics Company Details
7.2.2 C4 Therapeutics Business Overview
7.2.3 C4 Therapeutics Targeted Protein Degrader Technology Introduction
7.2.4 C4 Therapeutics Revenue in Targeted Protein Degrader Technology Business (2021-2026)
7.2.5 C4 Therapeutics Recent Development
7.3 Kymera Therapeutics
7.3.1 Kymera Therapeutics Company Details
7.3.2 Kymera Therapeutics Business Overview
7.3.3 Kymera Therapeutics Targeted Protein Degrader Technology Introduction
7.3.4 Kymera Therapeutics Revenue in Targeted Protein Degrader Technology Business (2021-2026)
7.3.5 Kymera Therapeutics Recent Development
7.4 Nurix
7.4.1 Nurix Company Details
7.4.2 Nurix Business Overview
7.4.3 Nurix Targeted Protein Degrader Technology Introduction
7.4.4 Nurix Revenue in Targeted Protein Degrader Technology Business (2021-2026)
7.4.5 Nurix Recent Development
7.5 Pfizer
7.5.1 Pfizer Company Details
7.5.2 Pfizer Business Overview
7.5.3 Pfizer Targeted Protein Degrader Technology Introduction
7.5.4 Pfizer Revenue in Targeted Protein Degrader Technology Business (2021-2026)
7.5.5 Pfizer Recent Development
7.6 Novartis
7.6.1 Novartis Company Details
7.6.2 Novartis Business Overview
7.6.3 Novartis Targeted Protein Degrader Technology Introduction
7.6.4 Novartis Revenue in Targeted Protein Degrader Technology Business (2021-2026)
7.6.5 Novartis Recent Development
7.7 MSD
7.7.1 MSD Company Details
7.7.2 MSD Business Overview
7.7.3 MSD Targeted Protein Degrader Technology Introduction
7.7.4 MSD Revenue in Targeted Protein Degrader Technology Business (2021-2026)
7.7.5 MSD Recent Development
7.8 Foghorn Therapeutics
7.8.1 Foghorn Therapeutics Company Details
7.8.2 Foghorn Therapeutics Business Overview
7.8.3 Foghorn Therapeutics Targeted Protein Degrader Technology Introduction
7.8.4 Foghorn Therapeutics Revenue in Targeted Protein Degrader Technology Business (2021-2026)
7.8.5 Foghorn Therapeutics Recent Development
7.9 Dialectic Therapeutics
7.9.1 Dialectic Therapeutics Company Details
7.9.2 Dialectic Therapeutics Business Overview
7.9.3 Dialectic Therapeutics Targeted Protein Degrader Technology Introduction
7.9.4 Dialectic Therapeutics Revenue in Targeted Protein Degrader Technology Business (2021-2026)
7.9.5 Dialectic Therapeutics Recent Development
7.10 Accutar Biotech
7.10.1 Accutar Biotech Company Details
7.10.2 Accutar Biotech Business Overview
7.10.3 Accutar Biotech Targeted Protein Degrader Technology Introduction
7.10.4 Accutar Biotech Revenue in Targeted Protein Degrader Technology Business (2021-2026)
7.10.5 Accutar Biotech Recent Development
7.11 Cullgen
7.11.1 Cullgen Company Details
7.11.2 Cullgen Business Overview
7.11.3 Cullgen Targeted Protein Degrader Technology Introduction
7.11.4 Cullgen Revenue in Targeted Protein Degrader Technology Business (2021-2026)
7.11.5 Cullgen Recent Development
7.12 Bristol-Myers Squibb
7.12.1 Bristol-Myers Squibb Company Details
7.12.2 Bristol-Myers Squibb Business Overview
7.12.3 Bristol-Myers Squibb Targeted Protein Degrader Technology Introduction
7.12.4 Bristol-Myers Squibb Revenue in Targeted Protein Degrader Technology Business (2021-2026)
7.12.5 Bristol-Myers Squibb Recent Development
7.13 Monte Rosa Therapeutics
7.13.1 Monte Rosa Therapeutics Company Details
7.13.2 Monte Rosa Therapeutics Business Overview
7.13.3 Monte Rosa Therapeutics Targeted Protein Degrader Technology Introduction
7.13.4 Monte Rosa Therapeutics Revenue in Targeted Protein Degrader Technology Business (2021-2026)
7.13.5 Monte Rosa Therapeutics Recent Development
7.14 Proxygen
7.14.1 Proxygen Company Details
7.14.2 Proxygen Business Overview
7.14.3 Proxygen Targeted Protein Degrader Technology Introduction
7.14.4 Proxygen Revenue in Targeted Protein Degrader Technology Business (2021-2026)
7.14.5 Proxygen Recent Development
7.15 Dunad Therapeutics
7.15.1 Dunad Therapeutics Company Details
7.15.2 Dunad Therapeutics Business Overview
7.15.3 Dunad Therapeutics Targeted Protein Degrader Technology Introduction
7.15.4 Dunad Therapeutics Revenue in Targeted Protein Degrader Technology Business (2021-2026)
7.15.5 Dunad Therapeutics Recent Development
7.16 Astellas
7.16.1 Astellas Company Details
7.16.2 Astellas Business Overview
7.16.3 Astellas Targeted Protein Degrader Technology Introduction
7.16.4 Astellas Revenue in Targeted Protein Degrader Technology Business (2021-2026)
7.16.5 Astellas Recent Development
7.17 Origami Therapeutics
7.17.1 Origami Therapeutics Company Details
7.17.2 Origami Therapeutics Business Overview
7.17.3 Origami Therapeutics Targeted Protein Degrader Technology Introduction
7.17.4 Origami Therapeutics Revenue in Targeted Protein Degrader Technology Business (2021-2026)
7.17.5 Origami Therapeutics Recent Development
7.18 NEOsphere Biotechnologies
7.18.1 NEOsphere Biotechnologies Company Details
7.18.2 NEOsphere Biotechnologies Business Overview
7.18.3 NEOsphere Biotechnologies Targeted Protein Degrader Technology Introduction
7.18.4 NEOsphere Biotechnologies Revenue in Targeted Protein Degrader Technology Business (2021-2026)
7.18.5 NEOsphere Biotechnologies Recent Development
7.19 Ubiquigent
7.19.1 Ubiquigent Company Details
7.19.2 Ubiquigent Business Overview
7.19.3 Ubiquigent Targeted Protein Degrader Technology Introduction
7.19.4 Ubiquigent Revenue in Targeted Protein Degrader Technology Business (2021-2026)
7.19.5 Ubiquigent Recent Development
7.20 Kangpu Biopharmaceuticals
7.20.1 Kangpu Biopharmaceuticals Company Details
7.20.2 Kangpu Biopharmaceuticals Business Overview
7.20.3 Kangpu Biopharmaceuticals Targeted Protein Degrader Technology Introduction
7.20.4 Kangpu Biopharmaceuticals Revenue in Targeted Protein Degrader Technology Business (2021-2026)
7.20.5 Kangpu Biopharmaceuticals Recent Development
7.21 Ranok Therapeutics
7.21.1 Ranok Therapeutics Company Details
7.21.2 Ranok Therapeutics Business Overview
7.21.3 Ranok Therapeutics Targeted Protein Degrader Technology Introduction
7.21.4 Ranok Therapeutics Revenue in Targeted Protein Degrader Technology Business (2021-2026)
7.21.5 Ranok Therapeutics Recent Development
7.22 BeiGene
7.22.1 BeiGene Company Details
7.22.2 BeiGene Business Overview
7.22.3 BeiGene Targeted Protein Degrader Technology Introduction
7.22.4 BeiGene Revenue in Targeted Protein Degrader Technology Business (2021-2026)
7.22.5 BeiGene Recent Development
7.23 Hinova Pharma
7.23.1 Hinova Pharma Company Details
7.23.2 Hinova Pharma Business Overview
7.23.3 Hinova Pharma Targeted Protein Degrader Technology Introduction
7.23.4 Hinova Pharma Revenue in Targeted Protein Degrader Technology Business (2021-2026)
7.23.5 Hinova Pharma Recent Development
7.24 Haisco Pharmaceutical
7.24.1 Haisco Pharmaceutical Company Details
7.24.2 Haisco Pharmaceutical Business Overview
7.24.3 Haisco Pharmaceutical Targeted Protein Degrader Technology Introduction
7.24.4 Haisco Pharmaceutical Revenue in Targeted Protein Degrader Technology Business (2021-2026)
7.24.5 Haisco Pharmaceutical Recent Development
7.25 CTTQ
7.25.1 CTTQ Company Details
7.25.2 CTTQ Business Overview
7.25.3 CTTQ Targeted Protein Degrader Technology Introduction
7.25.4 CTTQ Revenue in Targeted Protein Degrader Technology Business (2021-2026)
7.25.5 CTTQ Recent Development

8 Targeted Protein Degrader Technology Market Dynamics
8.1 Targeted Protein Degrader Technology Industry Trends
8.2 Targeted Protein Degrader Technology Market Drivers
8.3 Targeted Protein Degrader Technology Market Challenges
8.4 Targeted Protein Degrader Technology Market Restraints

9 Research Findings and Conclusion

10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Global Targeted Protein Degrader Technology Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Global Targeted Protein Degrader Technology Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
Table 3. Global Market Targeted Protein Degrader Technology Market Size (US$ Million) by Region:2021 vs 2025 vs 2032
Table 4. Global Targeted Protein Degrader Technology Revenue (US$ Million) Market Share by Region (2021-2026)
Table 5. Global Targeted Protein Degrader Technology Revenue Share by Region (2021-2026)
Table 6. Global Targeted Protein Degrader Technology Revenue (US$ Million) Forecast by Region (2027-2032)
Table 7. Global Targeted Protein Degrader Technology Revenue Share Forecast by Region (2027-2032)
Table 8. Global Targeted Protein Degrader Technology Market Size by Type (2021-2026) & (US$ Million)
Table 9. Global Targeted Protein Degrader Technology Market Share by Revenue, by Type (2021-2026)
Table 10. Global Targeted Protein Degrader Technology Forecasted Market Size by Type (2027-2032) & (US$ Million)
Table 11. Global Targeted Protein Degrader Technology Market Share by Revenue, by Type (2027-2032)
Table 12. Representative Players of Each Type
Table 13. Global Targeted Protein Degrader Technology Market Size by Application (2021-2026) & (US$ Million)
Table 14. Global Targeted Protein Degrader Technology Market Share by Revenue, by Application (2021-2026)
Table 15. Global Targeted Protein Degrader Technology Forecasted Market Size by Application (2027-2032) & (US$ Million)
Table 16. Global Targeted Protein Degrader Technology Market Share by Revenue, by Application (2027-2032)
Table 17. New Sources of Growth in Targeted Protein Degrader Technology Applications
Table 18. Global Targeted Protein Degrader Technology Revenue by Players (2021-2026) & (US$ Million)
Table 19. Global Targeted Protein Degrader Technology Market Share by Players (2021-2026)
Table 20. Global Top Targeted Protein Degrader Technology Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Protein Degrader Technology as of 2025)
Table 21. Ranking of Global Top Targeted Protein Degrader Technology Companies by Revenue (US$ Million) in 2025
Table 22. Global 5 Largest Players Market Share by Targeted Protein Degrader Technology Revenue (CR5 and HHI) & (2021-2026)
Table 23. Global Key Players of Targeted Protein Degrader Technology, Headquarters and Area Served
Table 24. Global Key Players of Targeted Protein Degrader Technology, Product and Application
Table 25. Global Key Players of Targeted Protein Degrader Technology, Date of Entry into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. North America Targeted Protein Degrader Technology Revenue by Company (2021-2026) & (US$ Million)
Table 28. North America Targeted Protein Degrader Technology Market Share by Revenue, by Company (2021-2026)
Table 29. North America Targeted Protein Degrader Technology Market Size by Type (2021-2026) & (US$ Million)
Table 30. North America Targeted Protein Degrader Technology Market Size by Application (2021-2026) & (US$ Million)
Table 31. Europe Targeted Protein Degrader Technology Revenue by Company (2021-2026) & (US$ Million)
Table 32. Europe Targeted Protein Degrader Technology Market Share by Revenue, by Company (2021-2026)
Table 33. Europe Targeted Protein Degrader Technology Market Size by Type (2021-2026) & (US$ Million)
Table 34. Europe Targeted Protein Degrader Technology Market Size by Application (2021-2026) & (US$ Million)
Table 35. Asia-Pacific Targeted Protein Degrader Technology Revenue by Company (2021-2026) & (US$ Million)
Table 36. Asia-Pacific Targeted Protein Degrader Technology Market Share by Revenue, by Company (2021-2026)
Table 37. Asia-Pacific Targeted Protein Degrader Technology Market Size by Type (2021-2026) & (US$ Million)
Table 38. Asia-Pacific Targeted Protein Degrader Technology Market Size by Application (2021-2026) & (US$ Million)
Table 39. Latin America Targeted Protein Degrader Technology Revenue by Company (2021-2026) & (US$ Million)
Table 40. Latin America Targeted Protein Degrader Technology Market Share by Revenue, by Company (2021-2026)
Table 41. Latin America Targeted Protein Degrader Technology Market Size by Type (2021-2026) & (US$ Million)
Table 42. Latin America Targeted Protein Degrader Technology Market Size by Application (2021-2026) & (US$ Million)
Table 43. Middle East & Africa Targeted Protein Degrader Technology Revenue by Company (2021-2026) & (US$ Million)
Table 44. Middle East & Africa Targeted Protein Degrader Technology Market Share by Revenue, by Company (2021-2026)
Table 45. Middle East & Africa Targeted Protein Degrader Technology Market Size by Type (2021-2026) & (US$ Million)
Table 46. Middle East & Africa Targeted Protein Degrader Technology Market Size by Application (2021-2026) & (US$ Million)
Table 47. Arvinas Company Details
Table 48. Arvinas Business Overview
Table 49. Arvinas Targeted Protein Degrader Technology Product
Table 50. Arvinas Revenue in Targeted Protein Degrader Technology Business (2021-2026) & (US$ Million)
Table 51. Arvinas Recent Development
Table 52. C4 Therapeutics Company Details
Table 53. C4 Therapeutics Business Overview
Table 54. C4 Therapeutics Targeted Protein Degrader Technology Product
Table 55. C4 Therapeutics Revenue in Targeted Protein Degrader Technology Business (2021-2026) & (US$ Million)
Table 56. C4 Therapeutics Recent Development
Table 57. Kymera Therapeutics Company Details
Table 58. Kymera Therapeutics Business Overview
Table 59. Kymera Therapeutics Targeted Protein Degrader Technology Product
Table 60. Kymera Therapeutics Revenue in Targeted Protein Degrader Technology Business (2021-2026) & (US$ Million)
Table 61. Kymera Therapeutics Recent Development
Table 62. Nurix Company Details
Table 63. Nurix Business Overview
Table 64. Nurix Targeted Protein Degrader Technology Product
Table 65. Nurix Revenue in Targeted Protein Degrader Technology Business (2021-2026) & (US$ Million)
Table 66. Nurix Recent Development
Table 67. Pfizer Company Details
Table 68. Pfizer Business Overview
Table 69. Pfizer Targeted Protein Degrader Technology Product
Table 70. Pfizer Revenue in Targeted Protein Degrader Technology Business (2021-2026) & (US$ Million)
Table 71. Pfizer Recent Development
Table 72. Novartis Company Details
Table 73. Novartis Business Overview
Table 74. Novartis Targeted Protein Degrader Technology Product
Table 75. Novartis Revenue in Targeted Protein Degrader Technology Business (2021-2026) & (US$ Million)
Table 76. Novartis Recent Development
Table 77. MSD Company Details
Table 78. MSD Business Overview
Table 79. MSD Targeted Protein Degrader Technology Product
Table 80. MSD Revenue in Targeted Protein Degrader Technology Business (2021-2026) & (US$ Million)
Table 81. MSD Recent Development
Table 82. Foghorn Therapeutics Company Details
Table 83. Foghorn Therapeutics Business Overview
Table 84. Foghorn Therapeutics Targeted Protein Degrader Technology Product
Table 85. Foghorn Therapeutics Revenue in Targeted Protein Degrader Technology Business (2021-2026) & (US$ Million)
Table 86. Foghorn Therapeutics Recent Development
Table 87. Dialectic Therapeutics Company Details
Table 88. Dialectic Therapeutics Business Overview
Table 89. Dialectic Therapeutics Targeted Protein Degrader Technology Product
Table 90. Dialectic Therapeutics Revenue in Targeted Protein Degrader Technology Business (2021-2026) & (US$ Million)
Table 91. Dialectic Therapeutics Recent Development
Table 92. Accutar Biotech Company Details
Table 93. Accutar Biotech Business Overview
Table 94. Accutar Biotech Targeted Protein Degrader Technology Product
Table 95. Accutar Biotech Revenue in Targeted Protein Degrader Technology Business (2021-2026) & (US$ Million)
Table 96. Accutar Biotech Recent Development
Table 97. Cullgen Company Details
Table 98. Cullgen Business Overview
Table 99. Cullgen Targeted Protein Degrader Technology Product
Table 100. Cullgen Revenue in Targeted Protein Degrader Technology Business (2021-2026) & (US$ Million)
Table 101. Cullgen Recent Development
Table 102. Bristol-Myers Squibb Company Details
Table 103. Bristol-Myers Squibb Business Overview
Table 104. Bristol-Myers Squibb Targeted Protein Degrader Technology Product
Table 105. Bristol-Myers Squibb Revenue in Targeted Protein Degrader Technology Business (2021-2026) & (US$ Million)
Table 106. Bristol-Myers Squibb Recent Development
Table 107. Monte Rosa Therapeutics Company Details
Table 108. Monte Rosa Therapeutics Business Overview
Table 109. Monte Rosa Therapeutics Targeted Protein Degrader Technology Product
Table 110. Monte Rosa Therapeutics Revenue in Targeted Protein Degrader Technology Business (2021-2026) & (US$ Million)
Table 111. Monte Rosa Therapeutics Recent Development
Table 112. Proxygen Company Details
Table 113. Proxygen Business Overview
Table 114. Proxygen Targeted Protein Degrader Technology Product
Table 115. Proxygen Revenue in Targeted Protein Degrader Technology Business (2021-2026) & (US$ Million)
Table 116. Proxygen Recent Development
Table 117. Dunad Therapeutics Company Details
Table 118. Dunad Therapeutics Business Overview
Table 119. Dunad Therapeutics Targeted Protein Degrader Technology Product
Table 120. Dunad Therapeutics Revenue in Targeted Protein Degrader Technology Business (2021-2026) & (US$ Million)
Table 121. Dunad Therapeutics Recent Development
Table 122. Astellas Company Details
Table 123. Astellas Business Overview
Table 124. Astellas Targeted Protein Degrader Technology Product
Table 125. Astellas Revenue in Targeted Protein Degrader Technology Business (2021-2026) & (US$ Million)
Table 126. Astellas Recent Development
Table 127. Origami Therapeutics Company Details
Table 128. Origami Therapeutics Business Overview
Table 129. Origami Therapeutics Targeted Protein Degrader Technology Product
Table 130. Origami Therapeutics Revenue in Targeted Protein Degrader Technology Business (2021-2026) & (US$ Million)
Table 131. Origami Therapeutics Recent Development
Table 132. NEOsphere Biotechnologies Company Details
Table 133. NEOsphere Biotechnologies Business Overview
Table 134. NEOsphere Biotechnologies Targeted Protein Degrader Technology Product
Table 135. NEOsphere Biotechnologies Revenue in Targeted Protein Degrader Technology Business (2021-2026) & (US$ Million)
Table 136. NEOsphere Biotechnologies Recent Development
Table 137. Ubiquigent Company Details
Table 138. Ubiquigent Business Overview
Table 139. Ubiquigent Targeted Protein Degrader Technology Product
Table 140. Ubiquigent Revenue in Targeted Protein Degrader Technology Business (2021-2026) & (US$ Million)
Table 141. Ubiquigent Recent Development
Table 142. Kangpu Biopharmaceuticals Company Details
Table 143. Kangpu Biopharmaceuticals Business Overview
Table 144. Kangpu Biopharmaceuticals Targeted Protein Degrader Technology Product
Table 145. Kangpu Biopharmaceuticals Revenue in Targeted Protein Degrader Technology Business (2021-2026) & (US$ Million)
Table 146. Kangpu Biopharmaceuticals Recent Development
Table 147. Ranok Therapeutics Company Details
Table 148. Ranok Therapeutics Business Overview
Table 149. Ranok Therapeutics Targeted Protein Degrader Technology Product
Table 150. Ranok Therapeutics Revenue in Targeted Protein Degrader Technology Business (2021-2026) & (US$ Million)
Table 151. Ranok Therapeutics Recent Development
Table 152. BeiGene Company Details
Table 153. BeiGene Business Overview
Table 154. BeiGene Targeted Protein Degrader Technology Product
Table 155. BeiGene Revenue in Targeted Protein Degrader Technology Business (2021-2026) & (US$ Million)
Table 156. BeiGene Recent Development
Table 157. Hinova Pharma Company Details
Table 158. Hinova Pharma Business Overview
Table 159. Hinova Pharma Targeted Protein Degrader Technology Product
Table 160. Hinova Pharma Revenue in Targeted Protein Degrader Technology Business (2021-2026) & (US$ Million)
Table 161. Hinova Pharma Recent Development
Table 162. Haisco Pharmaceutical Company Details
Table 163. Haisco Pharmaceutical Business Overview
Table 164. Haisco Pharmaceutical Targeted Protein Degrader Technology Product
Table 165. Haisco Pharmaceutical Revenue in Targeted Protein Degrader Technology Business (2021-2026) & (US$ Million)
Table 166. Haisco Pharmaceutical Recent Development
Table 167. CTTQ Company Details
Table 168. CTTQ Business Overview
Table 169. CTTQ Targeted Protein Degrader Technology Product
Table 170. CTTQ Revenue in Targeted Protein Degrader Technology Business (2021-2026) & (US$ Million)
Table 171. CTTQ Recent Development
Table 172. Targeted Protein Degrader Technology Market Trends
Table 173. Targeted Protein Degrader Technology Market Drivers
Table 174. Targeted Protein Degrader Technology Market Challenges
Table 175. Targeted Protein Degrader Technology Market Restraints
Table 176. Research Programs/Design for This Report
Table 177. Key Data Information from Secondary Sources
Table 178. Key Data Information from Primary Sources

List of Figures
Figure 1. Targeted Protein Degrader Technology Product Picture
Figure 2. Global Targeted Protein Degrader Technology Market Share by Type: 2025 vs 2032
Figure 3. PROTAC Features
Figure 4. Molecular Glues Features
Figure 5. Other Ubiquitin-Proteasome System Technologies Features
Figure 6. Lysosomal System Technologies Features
Figure 7. Global Targeted Protein Degrader Technology Market Share by Application: 2025 vs 2032
Figure 8. Prostate Cancer
Figure 9. Breast Cancer
Figure 10. Lymphoma
Figure 11. Others
Figure 12. Targeted Protein Degrader Technology Report Years Considered
Figure 13. Global Targeted Protein Degrader Technology Market Size (US$ Million), Year-over-Year: 2021-2032
Figure 14. Global Targeted Protein Degrader Technology Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 15. Global Targeted Protein Degrader Technology Market Share by Revenue, by Region: 2021 vs 2025
Figure 16. North America Targeted Protein Degrader Technology Revenue (US$ Million) Growth Rate (2021-2032)
Figure 17. Europe Targeted Protein Degrader Technology Revenue (US$ Million) Growth Rate (2021-2032)
Figure 18. Asia-Pacific Targeted Protein Degrader Technology Revenue (US$ Million) Growth Rate (2021-2032)
Figure 19. Latin America Targeted Protein Degrader Technology Revenue (US$ Million) Growth Rate (2021-2032)
Figure 20. Middle East & Africa Targeted Protein Degrader Technology Revenue (US$ Million) Growth Rate (2021-2032)
Figure 21. Global Targeted Protein Degrader Technology Market Share by Players in 2025
Figure 22. Global Top Targeted Protein Degrader Technology Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Protein Degrader Technology as of 2025)
Figure 23. The Top 10 and 5 Players Market Share by Targeted Protein Degrader Technology Revenue in 2025
Figure 24. North America Targeted Protein Degrader Technology Market Share by Type (2021-2026)
Figure 25. North America Targeted Protein Degrader Technology Market Share by Application (2021-2026)
Figure 26. Europe Targeted Protein Degrader Technology Market Share by Type (2021-2026)
Figure 27. Europe Targeted Protein Degrader Technology Market Share by Application (2021-2026)
Figure 28. Asia-Pacific Targeted Protein Degrader Technology Market Share by Type (2021-2026)
Figure 29. Asia-Pacific Targeted Protein Degrader Technology Market Share by Application (2021-2026)
Figure 30. Latin America Targeted Protein Degrader Technology Market Share by Type (2021-2026)
Figure 31. Latin America Targeted Protein Degrader Technology Market Share by Application (2021-2026)
Figure 32. Middle East & Africa Targeted Protein Degrader Technology Market Share by Type (2021-2026)
Figure 33. Middle East & Africa Targeted Protein Degrader Technology Market Share by Application (2021-2026)
Figure 34. Arvinas Revenue Growth Rate in Targeted Protein Degrader Technology Business (2021-2026)
Figure 35. C4 Therapeutics Revenue Growth Rate in Targeted Protein Degrader Technology Business (2021-2026)
Figure 36. Kymera Therapeutics Revenue Growth Rate in Targeted Protein Degrader Technology Business (2021-2026)
Figure 37. Nurix Revenue Growth Rate in Targeted Protein Degrader Technology Business (2021-2026)
Figure 38. Pfizer Revenue Growth Rate in Targeted Protein Degrader Technology Business (2021-2026)
Figure 39. Novartis Revenue Growth Rate in Targeted Protein Degrader Technology Business (2021-2026)
Figure 40. MSD Revenue Growth Rate in Targeted Protein Degrader Technology Business (2021-2026)
Figure 41. Foghorn Therapeutics Revenue Growth Rate in Targeted Protein Degrader Technology Business (2021-2026)
Figure 42. Dialectic Therapeutics Revenue Growth Rate in Targeted Protein Degrader Technology Business (2021-2026)
Figure 43. Accutar Biotech Revenue Growth Rate in Targeted Protein Degrader Technology Business (2021-2026)
Figure 44. Cullgen Revenue Growth Rate in Targeted Protein Degrader Technology Business (2021-2026)
Figure 45. Bristol-Myers Squibb Revenue Growth Rate in Targeted Protein Degrader Technology Business (2021-2026)
Figure 46. Monte Rosa Therapeutics Revenue Growth Rate in Targeted Protein Degrader Technology Business (2021-2026)
Figure 47. Proxygen Revenue Growth Rate in Targeted Protein Degrader Technology Business (2021-2026)
Figure 48. Dunad Therapeutics Revenue Growth Rate in Targeted Protein Degrader Technology Business (2021-2026)
Figure 49. Astellas Revenue Growth Rate in Targeted Protein Degrader Technology Business (2021-2026)
Figure 50. Origami Therapeutics Revenue Growth Rate in Targeted Protein Degrader Technology Business (2021-2026)
Figure 51. NEOsphere Biotechnologies Revenue Growth Rate in Targeted Protein Degrader Technology Business (2021-2026)
Figure 52. Ubiquigent Revenue Growth Rate in Targeted Protein Degrader Technology Business (2021-2026)
Figure 53. Kangpu Biopharmaceuticals Revenue Growth Rate in Targeted Protein Degrader Technology Business (2021-2026)
Figure 54. Ranok Therapeutics Revenue Growth Rate in Targeted Protein Degrader Technology Business (2021-2026)
Figure 55. BeiGene Revenue Growth Rate in Targeted Protein Degrader Technology Business (2021-2026)
Figure 56. Hinova Pharma Revenue Growth Rate in Targeted Protein Degrader Technology Business (2021-2026)
Figure 57. Haisco Pharmaceutical Revenue Growth Rate in Targeted Protein Degrader Technology Business (2021-2026)
Figure 58. CTTQ Revenue Growth Rate in Targeted Protein Degrader Technology Business (2021-2026)
Figure 59. Bottom-up and Top-down Approaches for This Report
Figure 60. Data Triangulation
Figure 61. Key Executives Interviewed